Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 29, 2022 5:39pm
237 Views
Post# 35138016

RE:RE:RE:Ever get the feeling that:

RE:RE:RE:Ever get the feeling that:Money $$$ talks.
Onc has stated, they want a bumdled deal.
that being a partner to work through both MBc & panc cancers .
However if Roche comes along with a reasonable offer , for just Panc....it will be accepted.
The best way to bundle the various cancer opportunities is to buy the whole thing.
Stay tuned, only 5 more trading days, until more data at the SAn Antonio symposium.
I don't expect any " deals" announced before or during  the symposium.
I do expect good data , worthy of corporate discussions.
When, oh when will be first business development be announced.?
Never in my 20 years of following Onc, have I seen such opportunities.
both in breadth & depth.
like I said. By early January there will be very little stones to over turn.
So we wait 

<< Previous
Bullboard Posts
Next >>